Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | POLQ | O75417 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 2/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL666126 | 0.83 | OPRM1 (0.53) | POLBMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL19187466 | 0.82 | POLQ (0.56) | POLBMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL6028292 | 0.82 | POLB (0.42) | POLBMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL23355845 | 0.81 | MEN1 (0.51) | POLBMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL5141980 | 0.81 | MEN1 (0.51) | POLBMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL4162403 | 0.80 | MEN1 (0.50) | POLBMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL2558035 | 0.80 | MEN1 (0.50) | POLBMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL5508940 | 0.79 | POLB (0.60) | POLBMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL2562392 | 0.78 | POLB (0.51) | POLBMEN1KMT2AGAASMN1; SMN2 | |
| SCHEMBL4036418 | 0.78 | GAA (0.54) | POLBMEN1KMT2AGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8168668-B2 | Compounds | ASTRAZENECA AB (SE) | 2012-05-01 | — | — | US | disclosed |
| US-20100286202-A1 | New Compounds | ASTRAZENECA AB (SE) | 2010-11-11 | — | — | US | disclosed |
| US-7618993-B2 | Compounds | ASTRAZENECA AB (SE) | 2009-11-17 | — | — | US | disclosed |
| US-20080171770-A1 | Compounds | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100286202-A1 | New Compounds | REN, PCSK9, FURIN | POLB 2337/4885MEN1 660/4885KMT2A 4014/4885 |
| US-20080171770-A1 | Compounds | REN, PCSK9, SLC10A1 | POLB 2234/4885MEN1 544/4885KMT2A 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.